BEMEQ: Burden Ethnographic Modeling Evaluation Qaujilisaaqtuq (BEMEQ) RSV: The Nunavut and Nunavik burden study

Principal Investigator: Dr. Rachel Dwillow

1. Determine rate and outcomes of ARI hospitalizations in infants in each of the three administrative regions of Nunavut and in Nunavik over a 10 year period
2. Determine rate and outcomes of RSV, influenza and other pathogen-specific hospitalizations in infants in each of the three administrative regions of Nunavut and in Nunavik over a 10 year period
3. Assess the effectiveness of palivizumab in preventing RSV admissions as administered in the Nunavut and Nunavik programs
4. Determine the variables associated with disease severity outcomes.
5. Compare the rate of ARI admissions (total and RSV- associated) for healthy term infants in Nunavut and Nunavik, before and after the introduction of the palivizumab program in healthy term infants in Nunavik in 2016.
6. Assess the potential indirect impact of the COVID-19 pandemic measures on the burden of ARI admissions for children from Nunavut.